---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-26-000023"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:31:41.451524+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands

## Summary
- Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
- GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.
- Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.
- Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.
- FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided.

## SEC filing metadata
- accession: 0000879169-26-000023
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/0000879169-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-26-000023
- JSON: https://secwatch.observer/filing/0000879169-26-000023.json
- Plain text: https://secwatch.observer/filing/0000879169-26-000023.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported first quarter of 2026 results: revenue $1.27 billion.
  - Period: first quarter of 2026
  - Revenue: $1.27 billion
  - Result: reported results
  source text: furnished as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/0000879169-26-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.